

#39

Sheet 1 of 2

FORM PTO 1449 (modified)		Atty. Docket No. X-10097	Serial No 08/484,542
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Brader, et al.	
		Filing Date June 7, 1995	Group 1631

O I P E APR 29 2003

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MPA	AA	US 6,465,426	10-15-2002	Brader	
	AB	US 6,531,448	11-03-2003	Brader	
↓	AC	US 5,008,241	04-16-1991	Markussen	
	AD				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number 4-Kind Code ⁵ (if known)				
MPA	BA	EP 280 534 B1	04-21-1993	Novo Nordisk		
	BB					

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
MPA	CA	Claims for U.S. Application No. 10/010,038 (9 pages)	
do not print	CB	Claims for U.S. Application No. 10/338,101	
do not print	CC	Notice of Opposition by Eli Lilly and Company against EP 792 290 B1	
do not print	CD	Response by Patentee to Opposition of EP 792 290 B1	
do not print	CE	Statement of Grounds of Opposition by Eli Lilly and Company against Australian Patent App. No. 682061	
	CF	Decision of a Delegate of the Commissioner of Patents re: Patent Appl. No. 682061	

BEST AVAILABLE COPY

Examiner Signature	Marianne P. Allen	Date Considered	8/13/03
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O I P E
APR 29 2003
PATENT & TRADEMARK OFFICE
S

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	
--	--

Atty. Docket No. X-10097	Serial No 08/484,542
Applicants Brader, et al.	
Filing Date June 7, 1995	Group 1631

MPA

do not print

MPA

MPA

	CG	Statutory Declaration by DONALD JOHN CHISHOLM dated 9-4-1998.	
	CH	Statutory Declaration by PETER DALRYMPLE JEFFREY dated 4-14-1998	
	CI	Statutory Declaration by JAN MARKUSSEN dated 6-11-1999	
	CJ	Statutory Declaration by STEPHEN COLAGIURI dated 6-15-1999	
	CK	Statutory Declaration by MILTON T.W. HEARN dated 6-15-1999	
	CL	Statutory Declaration by PETER DALRYMPLE JEFFREY dated 1-17-2000	
	CM	Statutory Declaration by ALFRED WIDMER dated 6-17-2000	
	CN	Statutory Declaration by MILTON T.W. HEARN dated 5-3-2000	
	CO	Statutory Declaration by PETER DALRYMPLE JEFFREY dated 7-6-2000	
	CP	Statutory Declaration by ALFRED WIDMER dated 7-4-2000	
	CQ	BRANGE, J. AND LANGKJÆR, L., "Chemical stability of insulin: 3. Influence of excipients, formulation and pH," Acta Pharm. Nord. 4(3), 149-158 (1992).	
	CR	KURTZHALS, P., HAVELUND, S., JONASSEN, I., KIEHR, B., RIBEL, U., and MARKUSSEN, J., "Albumin Binding and Time Action of Acylated Insulins in Various Species," Journal of Pharmaceutical Sciences, 85(3) 304-308 (March 1996).	
	CS	MARKUSSEN, J., HAVELUND, S., KURTZHALS, P., ANDERSEN, A., HALSTROM, J., HASSELAGER, E., LARSEN, U., RIBEL, U., SCHAFFER, L., VAD, K., JONASSEN, I., "Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs," Diabetologia, vol. 39, 281-288 (1996).	

BEST AVAILABLE COPY

Examiner Signature	Marianne P. Allen	Date Considered	8/13/03
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.